Research programme: TNF-alpha inhibitors - Biota Holdings
Latest Information Update: 29 May 2007
At a glance
- Originator Biota Holdings
- Class Small molecules
- Mechanism of Action Tumour necrosis factor alpha inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 24 Nov 2003 Preclinical trials in Rheumatoid arthritis in Australia (unspecified route)